04.08.2022 - Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today issued its financial results for the second quarter ended June 30, 2022. Amounts, unless specified otherwise, are expressed in U.S. dollars. Second Quarter 2022 and Recent .
10.05.2022 - Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today issued its financial results for the first quarter ended March 31, 2022. Amounts, unless specified otherwise, are expressed in U.S. dollars. Net product revenues were $21.6 .
14.7 million in net revenue for the third quarter 2021 Steady increases in LUPKYNIS Patient Start Forms, Conversion Rates and Payer Coverage Addition of two preclinical assets with potential in rare autoimmune conditions to grow and diversify the pipeline Conference call to be hosted today at 8:30 a.m. ET Aurinia Pharmaceuticals Inc. today issued its financial results for the third quarter ended September 30, 2021. .
Aurinia Announces Updated Interim Results from the AURORA 2 Continuation Study of LUPKYNIS for the Treatment of Lupus Nephritis investingnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investingnews.com Daily Mail and Mail on Sunday newspapers.